Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: A nationwide cohort study

Joint Bone Spine

Volumn 83, Issue 3, 2016, Pages 307-313

  Tseng, Chia Chun ^a,b   Chang, Shun Jen ^c   Tsai, Wen Chan ^b   Ou, Tsan Teng ^b   Wu, Cheng Chin ^b   Sung, Wan Yu ^a,b   Hsieh, Ming Chia ^d,e   Yen, Jeng Hsien ^a,b,f  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL UNIVERSITY OF KAOHSIUNG   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Diabetes; Hazard rate; Retrospective cohort study; Systemic sclerosis

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; STANDARDIZED INCIDENCE RATIO; SYSTEMIC SCLEROSIS; VERY ELDERLY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; SCLERODERMA, SYSTEMIC; TAIWAN; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TAIWAN; YOUNG ADULT;

EID: 84949661918     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.06.017     Document Type: Article

References (40)

1. [1] Man, A., Zhu, Y., Zhang, Y., et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis 72 (2013), 1188–1193.
2. [2] Lohmann, T., Sessler, J., Verlohren, H.J., et al. Distinct genetic and immunological features in patients with onset of IDDM before and after age 40. Diabetes Care 20 (1997), 524–529.
3. [3] Lo, S.F., Chang, S.N., Muo, C.H., et al. Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. Int J Cancer 132 (2013), 182–188.
4. [4] Költő, G., Faludi, R., Aradi, D., et al. Impact of cardiac involvement on the risk of mortality among patients with systemic sclerosis: a 5-year follow-up of a single-center cohort. Clin Rheumatol 33 (2014), 197–205.
5. [5] Ngian, G.S., Sahhar, J., Proudman, S.M., et al. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis 71 (2012), 1980–1983.
6. [6] Chang, C.H., Lin, J.W., Wu, L.C., et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 55 (2012), 1462–1472.
7. [7] Lai, C.C., Wang, S.H., Chen, W.S., et al. Increased risk of osteoporotic fractures in patients with systemic sclerosis: a nationwide population-based study. Ann Rheum Dis, 2014, 10.1136/annrheumdis-2013-204832.
8. [8] Huang, Y.W., Yang, S.S., Fu, S.C., et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. Hepatology 60 (2014), 807–814.
9. [9] Lin, W.H., Li, C.Y., Wang, W.M., et al. Incidence of end stage renal disease among type 1 diabetes: a nationwide cohort study in Taiwan. Medicine (Baltimore), 93, 2014, e274.
10. [10] Wu, C.S., Gau, S.S., Lai, M.S., Long-term antidepressant use and the risk of type 2 diabetes mellitus: a population-based, nested case-control study in Taiwan. J Clin Psychiatry 75 (2014), 31–38.
11. [11] Greenland, S., Rothman, K.J., Introduction to stratified analysis. Rothman, K.J., Greenland, S., Lash, T.L., (eds.) Modern epidemiology, 3rd ed, 2008, Lippincott Williams & Wilkins, Philadelphia, 252–282.
12. [12] Vettori, S., Cuomo, G., Iudici, M., et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol 34 (2014), 663–668.
13. [13] Rasche, S.S., Phillips, M., McInerney, M.F., et al. IL-13Rα1 expression on β-cell–specific T cells in NOD mice. Diabetes 60 (2011), 1716–1725.
14. [14] Jiang, L.Q., Franck, N., Egan, B., et al. Autocrine role of interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7. Am J Physiol Endocrinol Metab 305 (2013), E1359–E1366.
15. [15] Russell, M.A., Cooper, A.C., Dhayal, S., et al. Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells. Islets 5 (2013), 95–105.
16. [16] Azab, N.A., Rady, H.M., Marzouk, S.A., Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol 31 (2012), 1359–1364.
17. [17] Tornese, G., Iafusco, D., Monasta, L., et al. The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. Acta Diabetol 51 (2014), 239–246.
18. [18] Xiang, G., Zhang, J., Ling, Y., et al. Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients. Clin Endocrinol (Oxf) 80 (2014), 228–234.
19. [19] Mi, Q.S., Ly, D., Lamhamedi-Cherradi, S.E., et al. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 52 (2003), 1967–1975.
20. [20] Kang, S., Park, S.Y., Lee, H.J., et al. TRAIL upregulates decoy receptor 1 and mediates resistance to apoptosis in insulin-secreting INS-1 cells. Biochem Biophys Res Commun 396 (2010), 731–735.
21. [21] Yu, M.Y., Zhao, P.Q., Yan, X.H., et al. Association between the TRAIL single nucleotide polymorphism rs1131580 and type 2 diabetes mellitus in a Han Chinese population. Genet Mol Res 12 (2013), 3455–3464.
22. [22] Dziankowska-Bartkowiak, B., Zalewska, A., Sysa-Jedrzejowska, A., Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients. Med Sci Monit 10 (2004), CR202–CR208.
23. [23] Kikodze, N., Pantsulaia, I., Rekhviashvili, K., et al. Cytokines and T regulatory cells in the pathogenesis of type 1 diabetes. Georgian Med News 222 (2013), 29–35.
24. [24] Yaghini, N., Mahmoodi, M., Asadikaram, G.R., et al. Serum levels of interleukin 10 (IL-10) in patients with type 2 diabetes. Iran Red Crescent Med J, 13, 2011, 752.
25. [25] Peng, W.J., Wang, B.X., Pan, H.F., et al. Association of the interleukin-10 1082G/A, 819C/T and 3575T/A gene polymorphisms with systemic sclerosis: a meta-analysis. Mol Biol Rep 39 (2012), 6851–6855.
26. [26] Ide, A., Kawasaki, E., Abiru, N., et al. Genetic association between interleukin-10 gene promoter region polymorphisms and type 1 diabetes age-at-onset. Hum Immunol 63 (2002), 690–695.
27. [27] Zhang, F., Yang, Y., Lei, H., et al. A meta-analysis about the association between -1082G/A and -819C/T polymorphisms of IL-10 gene and risk of type 2 diabetes. Hum Immunol 74 (2013), 618–626.
28. [28] Tai, N., Yasuda, H., Xiang, Y., et al. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol 139 (2011), 336–349.
29. [29] Kim, H.J., Higashimori, T., Park, S.Y., et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53 (2004), 1060–1067.
30. [30] Blüher, M., Fasshauer, M., Tönjes, A., et al. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 113 (2005), 534–537.
31. [31] Mok, C.C., Chan, P.T., Chan, K.L., et al. Prevalence and risk factors of low bone mineral density in Chinese patients with systemic sclerosis: a case-control study. Rheumatology (Oxford) 52 (2013), 296–303.
32. [32] Hwang, L.C., Bai, C.H., Sun, C.A., et al. Prevalence of metabolically healthy obesity and its impacts on incidences of hypertension, diabetes and the metabolic syndrome in Taiwan. Asia Pac J Clin Nutr 21 (2012), 227–233.
33. [33] Battaglia, S., Bellia, M., Serafino-Agrusa, L., et al. Physical capacity in performing daily activities is reduced in scleroderma patients with early lung involvement. Clin Respir J, 2015, 10.1111/crj.12299.
34. [34] Long, G.H., Johansson, I., Rolandsson, O., et al. Healthy behaviours and 10-year incidence of diabetes: a population cohort study. Prev Med 71 (2015), 121–127.
35. [35] Morelli, S., Ferri, C., Di Francesco, L., et al. Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension. Ann Rheum Dis 54 (1995), 730–734.
36. [36] Kotyla, P.J., Gozdzik, J., Lewicki, M., et al. Serum lipid profile in patients with systemic sclerosis: relationship to the thyreometabolic state. Rheumatol Int 26 (2006), 583–584.
37. [37] Blackburn, D., Hux, J., Mamdani, M., Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 17 (2002), 717–720.
38. [38] Gallo, R., Natale, M., Vendrame, F., et al. In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. Acta Diabetol 49 (2012), S123–S131.
39. [39] Kauschansky, A., Frydman, M., Assa, S., et al. D-penicillamine-induced pancreatic islet autoantibody production is independent of the immunogenetic background: a lesson from patients with Wilson's disease. Clin Immunol Immunopathol 89 (1998), 279–283.
40. [40] Harada, M., Makino, S., Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 27 (1984), 604–606.